Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
$7.63
-10.2%
$3.64
$1.84
$7.85
$10.61M1.08240,896 shs248,682 shs
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
$9.27
+1.3%
$7.33
$5.00
$17.40
$11.68M0.2745,342 shs1,212 shs
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$0.86
+0.3%
$0.95
$0.74
$9.00
$2.79M1.65196,349 shs3,248 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.70
+0.9%
$3.04
$1.68
$26.96
$9.84M0.54135,431 shs223,683 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
0.00%+8.28%+252.70%+300.94%+106.81%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
+0.83%+6.64%+32.92%+53.22%-26.46%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-0.58%+8.63%-12.11%-1.86%-29.51%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-14.25%-11.32%-60.81%-73.53%-89.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
1.1398 of 5 stars
3.52.00.00.00.60.00.0
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4.169 of 5 stars
3.75.00.04.80.01.71.3
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
2.8621 of 5 stars
3.55.00.00.00.61.70.6
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.6469 of 5 stars
3.52.00.04.60.63.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
3.00
Buy$14.0083.49% Upside
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
3.33
Buy$90.00870.87% Upside
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
3.00
Buy$3.00247.95% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.334,154.90% Upside

Current Analyst Ratings Breakdown

Latest VRAX, SNSE, XFOR, and SNPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$100.00
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
5/1/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
N/AN/AN/AN/A$4.33 per shareN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/A$30.52 per shareN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$6.33K440.29N/AN/A$1.26 per share0.68
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M3.84N/AN/A$3.90 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
-$12.77M-$10.08N/AN/AN/A-115.28%-58.31%N/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$6.06MN/A0.00N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.79N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest VRAX, SNSE, XFOR, and SNPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$6.20N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
N/A$0.04N/A$0.04N/AN/A
5/6/2025Q1 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$4.20-$5.40-$1.20-$0.27N/AN/A
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
N/AN/AN/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
N/A
72.59
72.59
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/A
6.82
6.82
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/A
7.27
7.13
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
10.34%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
10.50%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
8.61%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
2.73%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
23.20%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
45.10%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Synaptogenix, Inc. stock logo
SNPX
Synaptogenix
41.39 million1.35 millionNot Optionable
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
401.26 million968,000Not Optionable
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
53.23 million2.38 millionNot Optionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.67 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Synaptogenix stock logo

Synaptogenix NASDAQ:SNPX

$7.63 -0.87 (-10.24%)
As of 07/7/2025

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:SNSE

$9.27 +0.12 (+1.31%)
As of 12:15 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Virax Biolabs Group stock logo

Virax Biolabs Group NASDAQ:VRAX

$0.86 +0.00 (+0.26%)
As of 12:13 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.70 +0.02 (+0.89%)
As of 12:15 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.